167 related articles for article (PubMed ID: 20230760)
1. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
[TBL] [Abstract][Full Text] [Related]
2. Development of proteasome inhibitors in oncology and autoimmune diseases.
Bennett MK; Kirk CJ
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
4. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
5. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors in cancer therapy: lessons from the first decade.
Orlowski RZ; Kuhn DJ
Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
[TBL] [Abstract][Full Text] [Related]
8. The role of proteasome in malignant diseases.
Moran E; Nencioni A
J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Dorsey BD; Iqbal M; Chatterjee S; Menta E; Bernardini R; Bernareggi A; Cassarà PG; D'Arasmo G; Ferretti E; De Munari S; Oliva A; Pezzoni G; Allievi C; Strepponi I; Ruggeri B; Ator MA; Williams M; Mallamo JP
J Med Chem; 2008 Feb; 51(4):1068-72. PubMed ID: 18247547
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors as therapeutics.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Landis-Piwowar KR
Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of proteasome inhibitor action and resistance in cancer.
McConkey DJ; Zhu K
Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
16. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
Tsukamoto S; Yokosawa H
Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
